

Product Name: Tideglusib Revision Date: 01/10/2021

# **Product Data Sheet**

# **Tideglusib**

Cat. No.:	B1539
CAS No.:	865854-05-3
Formula:	C19H14N2O2S
M.Wt:	334.39
Synonyms:	
Target:	PI3K/Akt/mTOR Signaling
Pathway:	GSK-3
Storage:	Store at -20°C
	210

## Solvent & Solubility

	insoluble in EtOH; ins	soluble in H2O; $\geq$ 16.7 mg/mL i	n DMSO with gent	h gentle warming		
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg	
		1 mM	2.9905 mL	14.9526 mL	29.9052 mL	
		5 mM	0.5981 mL	2.9905 mL	5.9810 mL	
		10 mM	0.2991 mL	1.4953 mL	2.9905 mL	

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary

non-ATP-competitive GSK-3β inhibitor

#### IC<sub>50</sub> & Target

	Cell Viability Assay	and the second
	Cell Line:	Spodoptera frugiperda Sf21 cells(expressing N-terminal His6-tagged human
		recombinant GSK-3β)
In Vitro	Preparation method:	The solubility of this compound in DMSO >15 mg/mL. General tips for obtaining
		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
		shake it in the ultrasonic bath for a while. Stock solution can be stored below
		-20°C for several months.

1 | www.apexbt.com

	Reacting conditions:	$55\mu M$ for 1h at 25 °C .		
	Applications:	Tideglusib blocked GSK-3 $\beta$ irreversibly in Sf21 cells transfected with human		
		recombinant GSK-3β. It could prevent inflammation and neurodegeneration		
		under excitotoxic conditions.		
	Animal experiment			
In Vivo	Animal models:	Transgenic APPsw-tauvlw C57Bl6j/SJL/CBA mixed hybrid genetic		
	PErson	mice( overexpressing human mutant APP and a triple human tau mutation		
	A Contraction	(G272V, P301L and R406W at chromosome 17))		
	Dosage form:	Reconstituted in 26% peg400 (Polyethylene Glycol 400), 15% Chremophor E		
		and water; 200 mg/kg daily for consecutive months; oral gavage		
	Applications:	Treatment with tideglusib resulted in lower levels of tau phosphorylation,		
		decreased amyloid deposition and plaque-associated astrocytic proliferation,		
		protection of neurons in the entorhinal cortex and CA1 hippocampal subfield		
		against cell death, and prevention of memory deficits in this transgenic mouse		
	BIP	model		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility ma		
	Contraction of the second	slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		

### **Product Citations**

See more customer validations on www.apexbt.com.



[1] Domínguez JM, Fuertes A, et al, Evidence for irreversible inhibition of glycogen synthase kinase-3 by Tideglusib. J Biol Chem. 2012 Jan; 287(2): 893-904.

APERA

[2] Luna-Medina R1, Cortes-Canteli M, et al, NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci. 2007 May 23;27(21):5766-76.

[3] Serenóa L, Coma M, et al, A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009 Sep; 35(3): 359-67.

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable 2 | www.apexbt.com

under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APEBIC



**APExBIO Technology** 

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com











